Catapult Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Catapult Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-18,000	Closed	-$2.24M	–	233
2015 Q1	$2.24M	Buy	+18,000	New	+$1.91M	0.27%	124
2014 Q3	–	Sell	-85,000	Closed	-$5.29M	–	201
2014 Q2	$5.29M	Buy	+85,000	New	+$5.14M	0.59%	46
2014 Q1	–	Sell	-30,000	Closed	-$2.11M	–	200
2013 Q4	$2.11M	Buy	+30,000	New	+$2.04M	0.5%	58

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Catapult Capital Management's BMRN Position: Q2 2015 in Review

Catapult Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 18,000 shares — an estimated $2.24M sold.

Catapult Capital Management first reported a position in BMRN in Q4 2013 and held it in 3 quarters. The position peaked at $5.29M in Q2 2014. 392 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Catapult Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Catapult Capital Management sold 18,000 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $2.24M.
Catapult Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 3 quarters.
Catapult Capital Management's BioMarin Pharmaceuticals position peaked at $5.29M in Q2 2014.
392 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Catapult Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.